Trade Alert: President of Patient & Testing Services Of CareDx Alexander Johnson Has Sold Stock
Trade Alert: President of Patient & Testing Services Of CareDx Alexander Johnson Has Sold Stock
Some CareDx, Inc (NASDAQ:CDNA) shareholders may be a little concerned to see that the President of Patient & Testing Services, Alexander Johnson, recently sold a substantial US$1.1m worth of stock at a price of US$33.55 per share. That's a big disposal, and it decreased their holding size by 45%, which is notable but not too bad.
一些CareDx, Inc (納斯達克:CDNA)的股東可能會有點擔心看到患者和測試服務總裁Alexander Johnson最近以每股33.55美元的價格大量出售了價值110萬美元的股票。這是一次大規模的減持,使他們持有股份減少了45%,這是值得注意的,但並不算太糟糕。
CareDx Insider Transactions Over The Last Year
過去一年CareDx內部交易
Notably, that recent sale by Alexander Johnson is the biggest insider sale of CareDx shares that we've seen in the last year. That means that an insider was selling shares at around the current price of US$31.54. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. We note that this sale took place at around the current price, so it isn't a major concern, though it's hardly a good sign.
值得注意的是,Alexander Johnson最近的股票出售是我們在過去一年中看到的CareDx股票中最大的內部交易。這意味着一個內部人士正在以當前價格31.54美元左右出售股份。雖然我們通常不喜歡看到內部人士拋售股票,但如果交易發生在較低價格時,那就更令人擔憂了。我們注意到這次交易發生在當前價格左右,所以並不是一個主要問題,儘管這並不是一個好兆頭。
Insiders in CareDx didn't buy any shares in the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
在過去一年中,CareDx的內部人士沒有購買任何股份。您可以在下面看到公司和個人在過去12個月的內部交易的可視化描述。如果您點擊圖表,您可以看到所有的個體交易,包括股價、個體和日期!
I will like CareDx better if I see some big insider buys. While we wait, check out this free list of undervalued and small cap stocks with considerable, recent, insider buying.
如果我看到一些大量內部人買入的話,我會更喜歡caredx。在等待期間,可以查看這份免費的低估和小盤股股票列表,其中包括最近有相當規模的內部人買入。
Insider Ownership Of CareDx
caredx的內部人所有權
For a common shareholder, it is worth checking how many shares are held by company insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. It appears that CareDx insiders own 2.6% of the company, worth about US$42m. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.
對於普通股東,值得一看的是公司內部人持有多少股份。如果內部人擁有公司的大量股份,那對我來說是一個好跡象。看起來caredx的內部人擁有公司的2.6%,價值約4200萬美元。我們確實看到其他地方有更高水平的內部人所有權,但這些持股足以表明內部人和其他股東之間的一致性。
So What Does This Data Suggest About CareDx Insiders?
那麼這些數據對caredx的內部人有何含義?
Insiders haven't bought CareDx stock in the last three months, but there was some selling. And there weren't any purchases to give us comfort, over the last year. Insiders own shares, but we're still pretty cautious, given the history of sales. We'd practice some caution before buying! In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing CareDx. To assist with this, we've discovered 3 warning signs that you should run your eye over to get a better picture of CareDx.
內部人在過去三個月內沒有購買caredx股票,但有一些拋售。在過去一年內也沒有任何購買活動,這讓我們感到不安。內部人持有股份,但考慮到拋售歷史,我們仍然相當謹慎。在購買之前,最好謹慎一些!除了了解內部人的交易情況,了解面臨的風險也是有益的。爲此,我們發現了3個警示標誌,您應該仔細研究一下以更全面地了解caredx。
Of course CareDx may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
當然,caredx可能不是最佳的股票選擇。因此,您可能希望查看這些高質量公司的免費收藏。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
對於本文而言,內部人是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置,但不包括衍生交易或間接利益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。